About Us

Some Background Info

  Tumor markers are typically detected with laboratory methods like ELISA, PCR or CT. Those tests above are performed in a Hospital lab, or in a doctors' diagnostic lab, which are expensive and can take valuable time. 

Aprimus new finger stick method can be performed anywhere, such as home, doctors' office, or as a rapid test with immediate results in any diagnostics center, or hospital. The results are available typically within 10 minutes visually (qualitative assay), or via Aprimus proprietary meter (quantitative assay). 

  The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new cancer cases by 2050, a massive 77% increase from the estimated 20 million cases in 2022. 

• Global Cancer Market to reach close to $1T by mid 2030 
• CAGR 10.9% 
• USA to reach more than $400B, with CAGR 15.8%  

Biospace

  Shift towards precision medicine in oncology treatment, which includes the following factors

1. Tailoring treatments to the patient’s unique genetic information  

2. EARLY DETECTION METHODS (where Aprimus Technology is playing an important role) 

These key factors are needed for breakthrough in therapy.

Biomarker-driven diagnostics combined with integration of artificial intelligence (see e.g., STARGATE MISSION) 

in diagnostic are anticipated to revolutionize cancer care. 

  Several prototype tests have been developed and the required  sensitivity has been established